Label: POTASSIUM CHLORIDE solution
60687-341-45, view more60687-341-50, 60687-341-51, 60687-341-58, 60687-341-64, 60687-341-71, 60687-341-72
- Packager: American Health Packaging
- This is a repackaged label.
- Source NDC Code(s): 69238-1459
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Updated July 19, 2019
If you are a consumer or patient please visit this version.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE.
POTASSIUM CHLORIDE oral solution
Initial U.S. Approval: 1948
INDICATIONS AND USAGE
Potassium chloride is a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient ( 1)
DOSAGE AND ADMINISTRATION
Treatment of hypokalemia:
- Adults: Initial doses range from 40 to 100 mEq/day in 2 to 5 divided doses: limit doses to 40 mEq per dose. Total daily dose should not exceed 200 mEq ( 2.2)
- Pediatric patients aged birth to 16 years old: 2 to 4 mEq/kg/day in divided doses; not to exceed 1 mEq/kg as a single dose or 20 mEq whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy. Total daily dose should not exceed 100 mEq ( 2.3)
Maintenance or Prophylaxis of hypokalemia:
DOSAGE FORMS AND STRENGTHS
- Concomitant use with potassium sparing diuretics. ( 4)
WARNINGS AND PRECAUTIONS
- Gastrointestinal Irritation: Dilute before use, take with meals ( 5.1)
Table of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Administration and Monitoring
Monitor serum potassium and adjust dosages accordingly. For treatment of hypokalemia, monitor potassium levels daily or more often depending on the severity of hypokalemia until they return to normal. Monitor potassium levels monthly to biannually for maintenance or prophylaxis.
The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.
Dilute the potassium chloride solution with at least 4 ounces of cold water [see Warnings and Precautions (5.1)].
Take with meals or immediately after eating.
If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation.
2.2 Adult Dosing
Treatment of hypokalemia:
Daily dose range from 40 to 100 mEq. Give in 2 to 5 divided doses: limit doses to 40 mEq per dose. The total daily dose should not exceed 200 mEq in a 24 hour period.
Maintenance or Prophylaxis:
Typical dose is 20 mEq per day. Individualize dose based upon serum potassium levels.
Studies support the use of potassium replacement in digitalis toxicity. When alkalosis is present, normokalemia and hyperkalemia may obscure a total potassium deficit. The advisability of use of potassium replacement in the setting of hyperkalemia is uncertain.
2.3 Pediatric Dosing
Treatment of hypokalemia:
Pediatric patients aged birth to 16 years old: The initial dose is 2 to 4 mEq/kg/day in divided doses; do not exceed as a single dose 1 mEq/kg or 40 mEq, whichever is lower; maximum daily doses should not exceed 100 mEq. If deficits are severe or ongoing losses are great, consider intravenous therapy.
Maintenance or Prophylaxis
Pediatric patients aged birth to 16 years old: Typical dose is 1 mEq/kg/day. Do not exceed 3 mEq/kg/day.
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Gastrointestinal Irritation
May cause gastrointestinal irritation if administered un-diluted. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration (2.1)].
- 6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
7.1 Potassium-Sparing Diuretics
Use with potassium-sparing diuretic can produce severe hyperkalemia. Avoid concomitant use.
7.2 Angiotensin-Converting Enzyme Inhibitors
Use with angiotensin converting enzyme (ACE) inhibitors produces potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category C
Animal reproduction studies have not been conducted with potassium chloride. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.
8.2 Nursing Mothers
The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.
8.3 Pediatric Use
The safety and effectiveness of potassium chloride have been demonstrated in children with diarrhea and malnutrition from birth to 16 years.
8.4 Geriatric Use
Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly potentially fatal hyperkalemia can result.
Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).
Treatment measures for hyperkalemia include the following:
- Monitor closely for arrhythmias and electrolyte changes.
- Eliminate foods and medications containing potassium and of any agents with potassium-sparing properties such as potassium-sparing diuretics, ARBS, ACE inhibitors, NSAIDS, certain nutritional supplements and many others.
- Administer intravenous calcium gluconate if the patient is at no risk or low risk of developing digitalis toxicity.
- Administer intravenously 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1000 mL.
- Correct acidosis, if present, with intravenous sodium bicarbonate.
- Use exchange resins, hemodialysis, or peritoneal dialysis.
In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.
Potassium chloride, USP is a white granular powder. It is freely soluble in water and insoluble in alcohol. Chemically, potassium chloride, USP is K-Cl with a molecular mass of 74.55.
Oral Solution 10%: Each 15 mL of solution contains 1.5 g of potassium chloride, USP and the following inactive ingredients: citric acid anhydrous, FD&C Yellow #6, glycerin, methylparaben, natural/artificial orange flavor, propylene glycol, propylparaben, purified water, sodium citrate, sucralose.
Oral Solution 20%: Each 15 mL of solution contains 3 g of potassium chloride, USP and the following inactive ingredients: citric acid anhydrous, FD&C Yellow #6, glycerin, methylparaben, natural/artificial orange flavor, propylene glycol, propylparaben, purified water, sodium citrate, sucralose.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The potassium ion (K +) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function.
The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.
Potassium is a normal dietary constituent, and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.
Based on published literature, the rate of absorption and urinary excretion of potassium from KCl oral solution were higher during the first few hours after dosing relative to modified release KCl products. The bioavailability of potassium, as measured by the cumulative urinary excretion of K + over a 24 hour post dose period, is similar for KCl solution and modified release products.
16 HOW SUPPLIED/STORAGE AND HANDLING
Potassium chloride oral solution, USP, 10% (20 mEq per 15 mL) is supplied as a clear, orange colored solution having an orange flavor and odor, and is available as follows:
15 mL unit dose cups (20 mEq per 15 mL):
30 cups (3 x 10) NDC 60687-341-58
40 cups (4 x 10) NDC 60687-341-64
50 cups (5 x 10) NDC 60687-341-71
80 cups (8 x 10) NDC 60687-341-07
30 mL unit dose cups (40 mEq per 30 mL):
40 cups (4 x 10) NDC 60687-341-14
50 cups (5 x 10) NDC 60687-341-72
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
PROTECT from LIGHT.
DO NOT USE IF SEAL IS BROKEN.
American Health Packaging unit dose cups (see How Supplied section) contain drug product from Amneal Pharmaceuticals LLC as follows:
(20 mEq per 15 mL / 30 UD) NDC 60687-341-58 packaged from NDC 69238-1459
(20 mEq per 15 mL / 40 UD) NDC 60687-341-64 packaged from NDC 69238-1459
(20 mEq per 15 mL / 50 UD) NDC 60687-341-71 packaged from NDC 69238-1459
(20 mEq per 15 mL / 80 UD) NDC 60687-341-07 packaged from NDC 69238-1459
(40 mEq per 30 mL / 40 UD) NDC 60687-341-14 packaged from NDC 69238-1459
(40 mEq per 30 mL / 50 UD) NDC 60687-341-72 packaged from NDC 69238-1459
American Health Packaging
Columbus, OH 43217
- Package/Label Display Panel - Tray
- Package/Label Display Panel – Cup – 20 mEq per 15 mL – 15 mL
- Package/Label Display Panel – Cup – 20 mEq per 15 mL – 30 mL
INGREDIENTS AND APPEARANCE
potassium chloride solution
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:60687-341(NDC:69238-1459) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CHLORIDE 1.5 g in 15 mL Inactive Ingredients Ingredient Name Strength ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) FD&C YELLOW NO. 6 (UNII: H77VEI93A8) GLYCERIN (UNII: PDC6A3C0OX) METHYLPARABEN (UNII: A2I8C7HI9T) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PROPYLPARABEN (UNII: Z8IX2SC1OH) WATER (UNII: 059QF0KO0R) SODIUM CITRATE, UNSPECIFIED FORM (UNII: 1Q73Q2JULR) SUCRALOSE (UNII: 96K6UQ3ZD4) Product Characteristics Color orange (clear, orange) Score Shape Size Flavor ORANGE Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:60687-341-58 3 in 1 CASE 01/15/2019 1 NDC:60687-341-50 10 in 1 TRAY 1 NDC:60687-341-44 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 2 NDC:60687-341-64 4 in 1 CASE 01/15/2019 2 NDC:60687-341-50 10 in 1 TRAY 2 NDC:60687-341-44 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 3 NDC:60687-341-71 5 in 1 CASE 09/01/2018 3 NDC:60687-341-50 10 in 1 TRAY 3 NDC:60687-341-44 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 4 NDC:60687-341-07 8 in 1 CASE 01/15/2019 4 NDC:60687-341-50 10 in 1 TRAY 4 NDC:60687-341-44 15 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 5 NDC:60687-341-14 4 in 1 CASE 01/15/2019 5 NDC:60687-341-51 10 in 1 TRAY 5 NDC:60687-341-45 30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 6 NDC:60687-341-72 5 in 1 CASE 09/01/2018 6 NDC:60687-341-51 10 in 1 TRAY 6 NDC:60687-341-45 30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA210041 09/01/2018 Labeler - American Health Packaging (929561009) Establishment Name Address ID/FEI Business Operations American Health Packaging 929561009 repack(60687-341)